Univercells Technologies Partners with RoosterBio to Advance Scalable and Continuous Exosomes Manufacture
Summary
This partnership will optimize manufacturing of extracellular vesicles (EVs) using scalable and continuous bioprocessing technologies to propel the commercialization of regenerative therapies at affordable costs. The goal is to deliver complete solutions for exosomes manufacture, leveraging Univercells Technologies’ intensified and integrated platforms and RoosterBio’s hMSC bioprocess and highly engineered media systems. Through the use of intensified and integrated technologies, this joint effort will enable developers to accelerate timelines, reduce costs, and manufacture their regenerative therapies via a scalable, commercially viable platform. ”We are continuously seeking disruptive technologies to expand the impact of our innovative hMSC and EV products and bioprocess solutions”, stated Tim Kelly, CEO of RoosterBio. With optimized, scalable processes, Type 2 Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under 1 year.